01. Overview
How Carboplatin Is Used to Treat Mesothelioma
卡铂是一种常见的treatment for mesothelioma。Mesothelioma patients are typically given a combination of carboplatin and Alimta®, also known as pemetrexed, through an IV, to help slow down the spread of cancer. It takes about 60 minutes to give a patient an intravenous carboplatin treatment and is repeated every 21 days, depending on the patient’s individual case and treatment needs. Factors that may determine the dosage of carboplatin include a patient’s general health,stage of mesothelioma, age and how they respond to the treatment cycles.
可为先进阶段胸膜间皮瘤患者作为一线化疗选择，提供卡铂和培养基的联合疗法。万博专业版一项研究表明，Carboplatin联合培养基可能会延长生存率，而不是顺铂和培养基的组合。接受顺铂和培育物的患者的中位存活率为14.9个月，而那些给予的卡铂和培育植物的患者将存活15.7个月。
Additionally, unlike cisplatin, which tends to be harsher on a person’s body, carboplatin stays in the body longer and poses fewer health risks and side effects. Patients who undergo chemotherapy using carboplatin and pemetrexed will be given folic acid tablets, oral steroids and an injection of Vitamin B12 to further reduce side effects.
02. Side Effects
Possible Side Effects of Carboplatin
卡铂非常像顺铂，具有与之相关的各种副作用，但由于药物的组成，它们往往不太严重。医生将进行血液检验以确定剂量是否应改变或停止并监测整个过程中的肾功能。
Like most anti-cancer drugs, common side effects stemming from carboplatin use may include pain, nausea, hair loss or thinning, mouth sores, sore throat and swelling or redness near or at the injection site. Carboplatin may also cause several other severe side effects in rare cases.
Patients undergoing chemotherapy with carboplatin may suffer from lower red blood cell and white blood cell counts, and will have to take extra precautions to avoid getting sick. In most cases, symptoms caused by carboplatin will subside once the cancer treatment ends.
03. Studies
Studies Associated With Carboplatin
Numerousclinical trialsover the years have proven that carboplatin can serve as a suitable replacement for cisplatin in patients with mesothelioma who are unable to tolerate its side effects. According to the American Society of Clinical Oncology, several phase 1 and phase 2 studies using a combination of pemetrexed and carboplatin showed similar results as a phase 3 study using pemetrexed and cisplatin, the parent drug of carboplatin. Patients who received the combination of carboplatin and pemetrexed had a median survival of 13 – 14 months, with about 7 – 8 months progression-free. In comparison, pemetrexed and cisplatin have shown varied survival times in different studies, with many noting survival around 12 – 16 months.
A phase 2 study evaluated the efficacy of carboplatin and pemetrexed as a first-line treatment for unresectablepleural mesothelioma。Of the 62 patients treated, 55% achieved stable disease, meaning there was no spreading or growth of tumors. An additional 29% of patients saw a partial response to the treatment. Researchers noted an average overall survival of 14 months, with a median seven months before disease progression. The cell type was a big factor in varied life expectancy, withepithelialpatients surviving 16 months andsarcomatoid mesotheliomapatients surviving 11 months on average.
